Interpace Biosciences, Inc. (IDXG) Operating cash flow 2016–2025
Interpace Biosciences, Inc. (IDXG) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$5.8MFY2025 · since FY2016: -$7.6M → $5.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $5.8M | +25.5% |
| FY2024 | $4.6M | +22.6% |
| FY2023 | $3.8M | +149.3% |
| FY2022 | -$7.7M | +11.8% |
| FY2021 | -$8.7M | +37.6% |
| FY2020 | -$14.0M | +26.3% |
| FY2019 | -$19.0M | -118.6% |
| FY2018 | -$8.7M | +43.2% |
| FY2017 | -$15.3M | -100.6% |
| FY2016 | -$7.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice